BIOLASE Inc
NASDAQ:BIOL

Watchlist Manager
BIOLASE Inc Logo
BIOLASE Inc
NASDAQ:BIOL
Watchlist
Price: 0.1681 USD 1.51%
Updated: May 29, 2024

Gross Margin
BIOLASE Inc

34%
Current
35%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
34%
=
Gross Profit
16.7m
/
Revenue
49.2m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
BIOLASE Inc
NASDAQ:BIOL
5.6m USD
34%
US
Abbott Laboratories
NYSE:ABT
176.7B USD
55%
US
Intuitive Surgical Inc
NASDAQ:ISRG
142.7B USD
66%
US
Stryker Corp
NYSE:SYK
131B USD
64%
US
Boston Scientific Corp
NYSE:BSX
110.5B USD
69%
IE
Medtronic PLC
NYSE:MDT
106.4B USD
66%
US
Becton Dickinson and Co
NYSE:BDX
65.4B USD
41%
DE
Siemens Healthineers AG
XETRA:SHL
60.1B EUR
38%
US
Edwards Lifesciences Corp
NYSE:EW
52.5B USD
77%
US
Dexcom Inc
NASDAQ:DXCM
50.9B USD
63%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
362B CNY
65%
BIOLASE Inc
NASDAQ:BIOL
Country US
Market Cap 5.6m USD
Gross Margin
34%
Abbott Laboratories
NYSE:ABT
Country US
Market Cap 176.7B USD
Gross Margin
55%
Intuitive Surgical Inc
NASDAQ:ISRG
Country US
Market Cap 142.7B USD
Gross Margin
66%
Stryker Corp
NYSE:SYK
Country US
Market Cap 131B USD
Gross Margin
64%
Boston Scientific Corp
NYSE:BSX
Country US
Market Cap 110.5B USD
Gross Margin
69%
Medtronic PLC
NYSE:MDT
Country IE
Market Cap 106.4B USD
Gross Margin
66%
Becton Dickinson and Co
NYSE:BDX
Country US
Market Cap 65.4B USD
Gross Margin
41%
Siemens Healthineers AG
XETRA:SHL
Country DE
Market Cap 60.1B EUR
Gross Margin
38%
Edwards Lifesciences Corp
NYSE:EW
Country US
Market Cap 52.5B USD
Gross Margin
77%
Dexcom Inc
NASDAQ:DXCM
Country US
Market Cap 50.9B USD
Gross Margin
63%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Country CN
Market Cap 362B CNY
Gross Margin
65%

Profitability Report

View the profitability report to see the full profitability analysis for BIOLASE Inc.

Full Profitability Report

See Also

Summary
BIOL intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIOL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIOL stock valuation using valuation multiples.
Wall Street Estimates
BIOL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIOL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
34%
=
Gross Profit
16.7m
/
Revenue
49.2m
What is the Gross Margin of BIOLASE Inc?

Based on BIOLASE Inc's most recent financial statements, the company has Gross Margin of 34%.

ALPHA SPREAD
Join more than 141,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.